ZURICH, Switzerland, February 29, 2024
BC Platforms AG (hereafter “BC Platforms”) today announces that Tero Silvola, current CEO, is leaving the company, effective today. A new Executive office has been formed with current COO, Mikaela Bruhammar, appointed as interim CEO, together with CFO Kaj Työppönen.
During his 10 years tenure, Tero Silvola played a pivotal role in advancing BC Platforms’ position as a leading provider of genomic data management solutions. Under his leadership, the company expanded its global footprint and achieved significant milestones in leveraging data-driven insights to accelerate medical research and personalized healthcare initiatives. It has grown to become an international leader in Real-World-Data technology.
“I want to express my deepest gratitude to Tero for his exceptional leadership and contributions to BC Platforms,” said Laurent Samama, Chairman of the Board of Directors. “Tero’s vision and dedication have been instrumental in guiding BC Platforms through a period of growth and innovation, positioning the company as a global leader in Real World Data and personalized medicine platform. We wish him every success in his future ventures. Further, I want to express my confidence in the new leadership and BC Platforms organization to successfully drive the company strategy forward.”
Tero Silvola stated, “It has been a privilege to lead BC Platforms and work alongside such talented and passionate individuals. Together, we have achieved remarkable progress in advancing the field of genomic data management and empowering healthcare and life science organizations worldwide. I am confident that BC Platforms will continue to thrive under new leadership, and I am excited to embark on a new chapter in my next venture. I will take on a CEO position in another company and continue in my role as a board member at BC Platforms.”
Interim CEO Mikaela Bruhammar said, “The strategy and mission for BC Platforms remains: to be a leading real-world data, technology, and services provider. At BC Platforms, we are on a mission to enable life sciences, healthcare, and research organizations to deliver actionable insights from data, accelerating drug development, precision medicine and personalized care. We will now sharpen our focus and scale by maximizing the value of our unique and combined capabilities from the core of BC Platforms, and our recent acquisitions of Medexprim and 4Pharma.”
